Mineralys Drug Sustains Blood Pressure Reduction Ahead of FDA Decision

Mineralys Therapeutics

RADNOR, PA — Mineralys Therapeutics Inc. (Nasdaq: MLYS) reported that its experimental hypertension drug lorundrostat maintained significant blood pressure reductions through 48 weeks of treatment, providing additional clinical evidence as the Radnor-based biotechnology company approaches a December 22 decision deadline from the U.S. Food and Drug Administration.

The findings, presented November 8 at the American Heart Association’s Scientific Sessions 2026 in Chicago, showed an average 17.8 mmHg reduction in automated office systolic blood pressure from the original trial baseline. More than half of participants, or 56%, achieved systolic readings below 130 mmHg.

The results extend earlier findings from Mineralys’ Phase 3 Launch-HTN trial, which evaluated lorundrostat in adults whose hypertension remained uncontrolled despite treatment with multiple medications.

The FDA is reviewing lorundrostat for use alongside other antihypertensive medications, with a Prescription Drug User Fee Act target action date of December 22, 2026.

The pending decision represents a regulatory milestone for Mineralys, which is developing lorundrostat as a treatment targeting excess aldosterone production, a biological mechanism associated with difficult-to-control hypertension.

The latest findings come from Transform-HTN, an open-label extension study that followed participants who previously received lorundrostat in the randomized, placebo-controlled Launch-HTN trial.

Of 808 participants assigned to lorundrostat treatment groups in the original study, 632 entered the extension trial. Participants received an additional 36 weeks of treatment while continuing their existing blood pressure medications.

READ:  Mineralys Grants 26,040 Shares in New Employee Equity Awards

The efficacy analysis included 504 participants and demonstrated a 17.8 mmHg reduction in systolic blood pressure at Week 48 compared with the original Launch-HTN baseline, a statistically significant result (p<0.0001).

Blood pressure reductions were similar among participants taking two background antihypertensive medications and those receiving three or more.

“For patients whose blood pressure remains uncontrolled despite multiple medications, particularly those in high-risk populations disproportionately affected by hypertension, the question in practice is whether a treatment can deliver both rapid and sustained blood pressure control,” said Manish Saxena, clinical co-director of Queen Mary University of London’s William Harvey Clinical Research Centre and a hypertension specialist at Barts Health NHS Trust.

Saxena said the sustained reductions and the proportion of patients reaching systolic pressure below 130 mmHg were relevant to efforts to reduce long-term cardiovascular and kidney risks.

The extension study also provided additional safety data from prolonged exposure to lorundrostat.

Of the 632 participants, 583, or 92%, completed 48 weeks of follow-up. Serious adverse events occurred in 27 participants, representing 4.3% of the study population, with investigators considering two cases treatment-related.

Thirty-seven participants, or 5.9%, discontinued lorundrostat because of adverse events, including 10 participants, or 1.6%, who stopped treatment because of hyperkalemia, an elevation in blood potassium levels.

READ:  Mineralys Drug Sustains Blood Pressure Gains Ahead of FDA Decision

Hyperkalemia requiring a dose reduction, treatment interruption or discontinuation occurred in 32 participants, or 5.1%.

Investigators also observed early increases in serum potassium and decreases in estimated glomerular filtration rate, a measure of kidney function. Both measures remained stable through the remainder of the extension period.

Mineralys reported no new clinically relevant safety findings beyond those identified in Launch-HTN.

The open-label design allowed investigators to assess longer-term treatment outcomes but did not provide a continuous placebo-controlled comparison across the full 48-week period.

Participants had an average age of 61, with women accounting for 46% of the study population. Black or African American participants represented 25%, while 39% were Hispanic or Latino.

Nearly two-thirds had a body mass index of at least 30. At baseline, 41% were taking two antihypertensive medications, while 59% were receiving three or more.

Lorundrostat is an oral aldosterone synthase inhibitor designed to suppress production of aldosterone by targeting the CYP11B2 enzyme. Excess aldosterone can contribute to elevated blood pressure and related cardiovascular and kidney complications.

Mineralys is also investigating the drug’s potential in conditions associated with dysregulated aldosterone, including chronic kidney disease and obstructive sleep apnea.

READ:  Cabaletta Reports Yearlong Responses in Autoimmune Therapy Trials

The company has completed six late-stage clinical trials of lorundrostat, including the Phase 3 Launch-HTN and Phase 2 Advance-HTN studies that support its regulatory application.

“Across multiple large clinical trials that included a diverse set of patients, lorundrostat has repeatedly demonstrated its potential to improve blood pressure control in patients with difficult-to-treat hypertension,” said Mineralys Chief Executive Officer Jon Congleton.

The company estimates that fewer than half of patients with hypertension achieve their blood pressure targets using currently available medications, underscoring the potential demand for additional treatment options.

Hypertension was listed as a primary or contributing cause in more than 685,000 U.S. deaths in 2022, according to figures cited by Mineralys. The company also cited an estimated $219 billion annual economic burden associated with hypertension and related conditions in 2019.

The longer-term findings add to the clinical evidence supporting lorundrostat’s pending application, with the FDA’s December decision determining whether the investigational treatment can enter the U.S. hypertension market.

Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.